carcinoid tumour in 1991 underwent successful tricuspid and pulmonary valve replacements. On postoperative day 10, he developed hypotension, a fever, leukocytosis, and flushing. His hypotension was treated with a 200 lg octreotide iv bolus followed by a 150 lgÁhr -1 infusion, vasopressin, norepinephrine, and hydrocortisone. He also required tracheal intubation for ARDS (Pa0 2 :F I 0 2 ratio 96). After 72 hr of broad spectrum antibiotics and no clinical improvement, antiserotonin and antihistamine therapies were augmented with cyproheptadine, ranitidine, and serial octreotide boluses with an infusion of 1,500 lgÁhr -1 . These interventions improved his oxygenation (Pa0 2 :F I 0 2 ratio 162) and reduced his norepinephrine requirements. Following a methylene blue bolus (1 mgÁkg -1 ) and 12-hr infusion (0.5 mgÁkg -1 Áhr -1 ), all vasopressors were discontinued and his oxygenation improved (Pa0 2 :F I 0 2 ratio 297). Conclusion In a patient with a carcinoid crisis and ARDS refractory to conventional therapies, substantial hemodynamic and oxygenation improvements were observed following methylene blue administration. This case highlights the potential pathophysiologic role of bradykinin and methylene blue as an adjunct therapeutic option in carcinoid crises.
Résumé
Objectif Lors d'une crise carcinoïde, de nombreux agents vasoactifs, y compris les précurseurs de la bradykinine, la sérotonine et l'histamine, sont sécrétés par les cellules tumorales. Il a été démontré que la bradykinine augmentait la perméabilité vasculaire pulmonaire et l'hypotension dans des modèles animaux; toutefois, nous ne connaissons que peu ses effets in vivo ou la pharmacothérapie ciblée pendant une crise carcinoïde. Nous décrivons un cas de syndrome de détresse respiratoire aiguë (SDRA) dans une crise carcinoïde réfractaire aux traitements conventionnels anti-sérotonine et anti-histamine. Carcinoid tumours are well-differentiated neuroendocrine tumours with an estimated incidence of 1.20-2.12 per 100,000 people. 1 Metastatic and carcinoid heart disease are thought to be risk factors for the perioperative incidence of carcinoid crises, though the incidence is low among patients who receive the serotonin release inhibitor, octreotide. 2, 3 Carcinoid tumour cells, however, secrete a number of vasoactive agents, including serotonin, histamine, and kallikreins (which convert kininogen into bradykinin). 2 In a carcinoid crisis, which can manifest as hypotension, flushing, diarrhea, and bronchoconstriction, antiserotonin and antihistamine therapies have been traditional therapeutic options. 3 Importantly, bradykinin has been shown to increase pulmonary vascular permeability and produce hypotension in animals; however, little is known about pharmacologically modifying its effects in a carcinoid crisis. [4] [5] [6] Herein, we report a severe case of postoperative carcinoid crisis associated with acute respiratory distress syndrome (ARDS) that was refractory to conventional antiserotonin and antihistamine therapies. A rapid improvement in oxygenation and blood pressure was observed following administration of methylene blue, suggesting that methylene blue may be an adjunct treatment for shock and non-cardiogenic pulmonary edema associated with a carcinoid crisis.
Case report
Written consent for this case report was obtained from the patient. A 56-yr-old male with known liver metastases and symptomatic carcinoid heart disease who underwent resection of a small intestinal carcinoid tumour in 1991 was referred for valve replacement. His carcinoid symptoms were managed with Sandostatin LAR TM (40 mg every four weeks) depot injections until being discontinued three months prior to surgery. Preoperative cardiac imaging showed severely thickened and immobile tricuspid and pulmonic valve leaflets associated with severe regurgitation of both valves. The right ventricle was moderately-severely dilated with normal systolic function, and left ventricular systolic function was preserved. The patient underwent successful tricuspid and pulmonic valve replacements with 29-mm Medtronic Mosaic TM (Medtronic, Minneapolis, MN, USA) porcine valves, and he was managed intraoperatively with an octreotide infusion. Postoperatively, he had multiple selflimiting episodes of hypotension controlled with the addition of an octreotide infusion 100 lgÁhr -1 ; he also experienced transient right ventricle failure and acute kidney injury. On postoperative day (POD) 5, he was transferred from the cardiovascular intensive care unit (CVICU) to the ward where his octreotide infusion was discontinued with a plan to resume scheduled monthly Sandostatin LAR injections.
On POD 10, he was readmitted to the CVICU with hypotension, a fever (38.0°C), leukocytosis, and flushing. His hypotension was treated with a 200 lg octreotide iv bolus followed by a 150 lgÁhr 7 The right ventricular midcavity dimension was at the upper limit of normal (3.3 cm), and the tricuspid annular plane systolic excursion was 1.5 cm (normal[ 1.6 cm), suggesting mildly reduced right ventricular systolic function. 8 Prior to his respiratory deterioration, the patient did not receive blood products, and he denied dysphagia or aspiration. Given the presence of non-cardiogenic pulmonary edema and octreotide refractory hypotension, the patient was initially managed as septic shock and ARDS with broad spectrum antibiotics and low tidal volume ventilation. On POD 13, all preliminary blood, urine, and bronchoscopic alveolar lavage cultures were reported as negative, and an alternate diagnosis of severe carcinoid crisis was considered. The patient was given a 12-mg dose of cyproheptadine followed by 8 mg NG q8h and ranitidine 50 mg iv bid. Additionally, a 500 lg and two 250 lg iv octreotide boluses were administered, and the infusion was titrated to 1,500 lgÁhr -1 over a 20-hr period. These interventions improved the patient's oxygenation (Pa0 2 :F I 0 2 ratio 162) and substantially reduced norepinephrine requirements. A 1 mgÁkg -1 bolus of methylene blue followed by a 0.5 mgÁkg -1 Áhr -1 infusion over 12 hr was administered. Six hours after the infusion was completed, all vasopressors were discontinued and the Pa0 2 :F I 0 2 ratio had increased to 297. The patient's trachea was extubated on POD 19, and he was discharged to the ward on POD 26. The patient's chest x-ray on POD 30 is shown in Figure (b) . The patient was discharged home on Sandostatin LAR 30 mg depot every three weeks.
Discussion
This case report has two important findings. First, it builds on previously published reports of ARDS associated with carcinoid crisis by non-invasively quantifying left ventricular function and filling pressures. Second, we observed a substantial improvement in the patient's blood pressure and oxygenation when methylene blue was added to conventional carcinoid crisis therapies.
In a carcinoid crisis, tumour cells have multiple secretory products; though traditional therapeutic options have targeted only serotonin and histamine. 2 In animal models, bradykinin causes increased pulmonary vascular permeability, vasodilation, and hypotension. [4] [5] [6] These actions may be mediated in part through the activation of nitric oxide synthase. 9, 10 Methylene blue competitively inhibits the binding of nitric oxide to soluble guanylate cyclase, thereby preventing the downstream activation of cyclic guanosine monophosphate and smooth muscle relaxation. 11 A previous in vivo animal study has shown
Figure Chest that methylene blue significantly reduces the pulmonary vasodilatory response of bradykinin, though all studies have not supported this finding. 12, 13 The association between ARDS and carcinoid crisis has not been well described. A case of intraoperative noncardiogenic pulmonary edema occurring after mobilization of a pancreatic tumour has been reported in a 28-yr-old female who rapidly responded to intravenous furosemide monotherapy.
14 This case builds on this possible association by noninvasively quantifying left ventricular diastolic function, left ventricular end diastolic pressure, and the Pa0 2 :F I 0 2 ratio required for the diagnosis of ARDS. 15 Finally, the possible association between carcinoid crisis and ARDS in this case report is strengthened by attempts to exclude other common inhospital precipitants of ARDS.
This report also adds to the limited published experience of the use of methylene blue in carcinoid crises. In a previous report of a 74-yr-old male with carcinoid heart disease who developed refractory vasoplegic shock following tricuspid valve replacement, the administration of methylene blue (2 mgÁkg -1 over 30 min then 0.5 mgÁkg
Áhr -1 for six hours) resulted in the discontinuation of all vasopressors. 16 In this case, we hypothesize that elevated levels of bradykinin may have been a pathophysiologic mediator of this patient's ARDS and hypotension given the observed hemodynamic and oxygenation improvement following the addition of methylene blue to appropriate antiserotonin and antihistamine therapy.
The limitations of this case report merit consideration. First, the secretory products of the carcinoid tumour were not measured, thus a definitive pathophysiologic link between potential ARDS mediators and therapies cannot be established. Second, the patient showed clinical improvement prior to the administration of methylene blue, thus, some of the improvement may have been a continued response to conventional carcinoid crisis therapies.
In conclusion, this report adds to the limited descriptions of ARDS associated with carcinoid crises and to the limited published experience of methylene blue in carcinoid crises. We observed a rapid clinical improvement in a patient's oxygenation and blood pressure when methylene blue was added to conventional carcinoid crisis therapies. Future studies are required to determine optimal dosing and indications for methylene blue administration in carcinoid crises.
